(a) The controlled substances listed in this section are
included in Schedule III. Schedule III shall consist of the
drugs and other substances by whatever official name, common or
usual name, chemical name or brand name designated, listed in
this section.
(b) Stimulants.-Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system including its salts, isomers (whether optical, position
or geometric) and salts of such isomers whenever the existence
of such salts, isomers and salts of isomers is possible within
the specific chemical designation:
(i) Those compounds, mixtures or preparations in
dosage unit form containing any stimulant substances listed in
Schedule II which compounds, mixtures or preparations were
listed on August 25, 1971, as excepted in the Federal Register
as excepted compounds under section 21 C.F.R. part 1308.32, and
any other drug of the quantitative composition shown in that
list for those drugs or which is the same except that it
contains a lesser quantity of controlled substances;
(ii) Benzphetamine;
(iii) Chlorphentermine;
(iv) Clortermine;
(v) Phendimetrazine.
(c) Depressants.-Unless specifically excepted or listed in
another schedule, any material, compound, mixture or preparation
which contains any quantity of the following substances having a
depressant effect on the central nervous system:
(i) Any compound, mixture or preparation containing
any of the following or any salt thereof, and one (1) or more
other active medicinal ingredient not listed in any schedule:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital.
(ii) Any suppository dosage form containing any of
the following or any salt thereof, and approved by the food and
drug administration for marketing only as a suppository:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital.
(iii) Any substance which contains any quantity of a
derivative of barbituric acid or any salt thereof;
(iv) Chorhexadol;
(v) Repealed By Laws 1997, ch. 151, § 2.
(vi) Lysergic acid;
(vii) Lysergic acid amide;
(viii) Methyprylon;
(ix) Sulfondiethylmethane;
(x) Sulfonethylmethane;
(xi) Sulfonmethane;
(xii) Tiletamine and zolazepam or any salt thereof;
some trade or other names for a tiletamine-zolazepam combination
product: telazol; some trade or other names for tiletamine: 2-
(ethylamino)-2-(2-thienyl)-cyclohexanone; some trade or other
names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
flupyrazapon;
(xiii) Ketamine, its salts, isomers and salts of
isomers (some other names for ketamine include (±)-2-(2-
chlorophenyl)-2-(methylamino)-cyclohexanone);
(xiv) Any drug product containing gamma hydoxybutyric
acid, its salts, isomers and salts of isomers, for which an
application is approved under section 505 of the federal Food,
Drug and Cosmetic Act.
(d) Nalorphine.
(e) Narcotic drugs.-Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation containing any of the following narcotic drugs, or
their salts calculated as the free anhydrous base or alkaloid,
in limited quantities as set forth in paragraphs (i) through
(viii) of this subsection:
(i) Not more than one and eight-tenths (1.8) grams of
codeine per one hundred (100) milliliters or not more than
ninety (90) milligrams per dosage unit, with an equal or greater
quantity of an isoquinoline alkaloid of opium;
(ii) Not more than one and eight-tenths (1.8) grams
of codeine per one hundred (100) milliliters or not more than
ninety (90) milligrams per dosage unit, with one (1) or more
active, nonnarcotic ingredients in recognized therapeutic
amounts;
(iii) Not more than three hundred (300) milligrams of
dihydrocodeinone (hydrocodone) per one hundred (100) milliliters
or not more than fifteen (15) milligrams per dosage unit, with a
fourfold or greater quantity of an isoquinoline alkaloid of
opium;
(iv) Not more than three hundred (300) milligrams of
dihydrocodeinone (hydrocodone) per one hundred (100) milliliters
or not more than fifteen (15) milligrams per dosage unit, with
one (1) or more active, nonnarcotic ingredients in recognized
therapeutic amounts;
(v) Not more than one and eight-tenths (1.8) grams of
dihydrocodeine per one hundred (100) milliliters or not more
than ninety (90) milligrams per dosage unit, with one (1) or
more active, nonnarcotic ingredients in recognized therapeutic
amounts;
(vi) Not more than three hundred (300) milligrams of
ethylmorphine, per one hundred (100) milliliters or not more
than fifteen (15) milligrams per dosage unit, with one (1) or
more active, nonnarcotic ingredients in recognized therapeutic
amounts;
(vii) Not more than five hundred (500) milligrams of
opium per one hundred (100) milliliters or per one hundred (100)
grams, or not more than twenty-five (25) milligrams per dosage
unit, with one (1) or more active, nonnarcotic ingredients in
recognized therapeutic amounts;
(viii) Not more than fifty (50) milligrams of
morphine per one hundred (100) milliliters or per one hundred
(100) grams, with one (1) or more active, nonnarcotic
ingredients in recognized therapeutic amounts.
(f) The commissioner may except by rule any compound,
mixture, or preparation containing any stimulant or depressant
substance listed in subsections (b) and (c) of this section from
the application of all or any part of this act if the compound,
mixture, or preparation contains one (1) or more active
medicinal ingredients not having a stimulant or depressant
effect on the central nervous system, and if the admixtures are
included therein in combinations, quantity, proportion, or
concentration that vitiate the potential for abuse of the
substances which have a stimulant or depressant effect on the
central nervous system.
(g) Anabolic steroids. – For purposes of this subsection,
"anabolic steroid" means any drug or hormonal substance,
chemically and pharmacologically related to testosterone (other
than estrogens, progestins, corticosteroids and
dehydroepiandrosterone) and unless specifically excepted or
unless listed in another schedule, includes any of the following
or any ether, ester, salt or derivative of the following that
acts in the same manner on the human body:
(i) 3[beta],17-dihydro-5a-androstane;
(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane;
(iii) 5[alpha]-androstan-3,17-dione;
(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-
5[alpha]-androst-1-ene);
(v) 1-androstenediol (3[alpha],17[beta]-dihydroxy-
5[alpha]-androst-1-ene);
(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-
androst-4-ene);
(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-
androst-5-ene);
(viii) 1-androstenedione ([5[alpha]]-androst-1-en-
3,17-dione);
(ix) 4-androstenedione (androst-4-en-3,17-dione);
(x) 5-androstenedione (androst-5-en-3,17-dione);
(xi) Bolasterone (7[alpha],17[alpha]-dimethyl-
17[beta]-hydroxyandrost-4-en-3-one);
(xii) Boldenone (17[beta]-hydroxyandrost-1,4,-diene-
3-one);
(xiii) Calusterone (7[beta],17[alpha]-dimethyl-
17[beta],hydroxyandrost-4-en-3-one);
(xiv) Clostebol (4chloro-17[beta]-hydroxyandrost-4-
en-3-one);
(xv) Dehydrochloromethyltestosterone (4-chloro-
17[beta]-hydroxy-17[alpha]-methyl-androst-1,4dien-3-one);
(xvi) [Delta]1-dihydrotestosterone (also known as "1-
testosterone") (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
(xvii) 4-dihydrotestosterone (17[beta]-hydroxy-
androstan-3-one);
(xviii) Drostanolone (17[beta]-hydroxy-2[alpha]-
methyl-5[alpha]-androstan-3-one);
(xix) Ethylestrenol (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-ene);
(xx) Fluoxymesterone (9-fluoro-17[alpha]-methyl-
11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
(xxi) Formebolone (2-formyl-17[alpha]-methyl-
11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
(xxii) Furazabol (17[alpha]-methyl-17[beta]-
hydroxyandrostano[2,3-c]-furazan);
(xxiii) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-
one);
(xxiv) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
androst-4-en-3-one);
(xxv) 4-hydroxy-19-nortestosterone (4,17[beta]-
dihydroxy-estr-4-en-3-one);
(xxvi) Mestanolone (17[alpha]-methyl-17[beta]-
hydroxy-5-androstan-3-one);
(xxvii) Mesterolone (1[alpha]-methyl-17[beta]-
hydroxy-[5[alpha]]-androstan-3-one);
(xxviii) Methandienone (17[alpha]-methyl-17[beta]-
hydroxyandrost-1,4-dien-3-one);
(xxix) Methandriol (17[alpha]-methyl-
3[beta],17[beta]-dihydroxyandrost-5-ene);
(xxx) Methenolone (1-methyl-17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one);
(xxxi) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-
5a-androstane);
(xxxii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-
5a-androstane);
(xxxiii) 17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-4-ene);
(xxxiv) 17[alpha]-methyl-4-hydroxynandrolone
(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
(xxxv) Methyldienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9(10)-dien-3-one);
(xxxvi) Methyltrienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9-11-trien-3-one);
(xxxvii) Methyltestosterone (17[alpha]-methyl-
17[beta]-hydroxyandrost-4-en-3-one);
(xxxviii) Mibolerone (7[alpha],17[alpha]-dimethyl-
17[beta]-hydroxyestr-4-en-3-one);
(xxxix) 17[alpha]-methyl-[Delta]1-dihydrotestosterone
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one)
(also known as "17-[alpha]-methyl-1-tesosterone");
(xl) Nandrolone (17[beta]-hydroxyestr-4-en-3-one);
(xli) 19-nor-4-androstenediol (3[beta], 17[beta]-
dihydroxyestr-4-ene);
(xlii) 19-nor-4-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-4-ene);
(xliii) 19-nor-5-androstenediol (3[beta], 17[beta]-
dihydroxyestr-5-ene);
(xliv) 19-nor-5-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-5-ene);
(xlv) 19-nor-4-androstenedione (estr-4-en-3,17-
dione);
(xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-
dione);
(xlvii) Norbolethone (13[beta],17[alpha]-diethyl-
17[beta]-hydroxygon-4-en-3-one);
(xlviii) Norclostebol (4-chloro-17[beta]-hydroxyestr-
4-en-3-one);
(xlix) Norethandrolone (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-en-3-one);
(l) Normethandrolone (17[alpha]-methyl-17[beta]-
hydroxyestr-4-en-3-one);
(li) Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
2-oxa-[5[alpha]]-androstan-3-one);
(lii) Oxymesterone (17[alpha]-methyl-4,17[beta]-
dihydroxyandrost-4-en-3-one);
(liii) Oxymetholone (17[alpha]-methyl-2-
hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3-one);
(liv) Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
[5[alpha]]-androst-2-eno[3,2-c]-pyrazole);
(lv) Stenbolone (17[beta]-hydroxy-2-methyl-
[5[alpha]]-androst-1-en-3-one);
(lvi) Testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic acid lactone);
(lvii) Testosterone (17[beta]-hydroxyandrost-4-en-3-
one);
(lviii) Tetrahydrogestrinone (13[beta], 17[alpha]-
diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
(lix) Trenbolone (17[beta]-hydroestr-4,9,11-trien-3-
one);
(lx) Boldione (androsta-1,4-diene-3,17-dione);
(lxi) Desoxymethyltestosterone (17[alpha]-methyl-
5[alpha]-androst- 2-en-17[beta]-ol)(also known as madol);
(lxii) 19-nor-4,9(10)-androstadienedione (estra-
4,9(10)-diene- 3,17-dione);
(lxiii) Any salt, ester or ether of a drug or
substance described or listed in this subsection, except the
term does not include an anabolic steroid which is expressly
intended for administration through implants to cattle or other
nonhuman species and which has been approved by the United
States secretary of health and humans services for such
administration. If any person prescribes, dispenses or
distributes such steroid for human use, the person shall be
considered to have prescribed, dispensed or distributed an
anabolic steroid within the meaning of this subsection.
(h) Hallucinogenic substances:
(i) Dronabinol (synthetic) in sesame oil and
encapsulated in a soft gelatin capsule in a United States Food
and Drug Administration approved drug product; some other names
for dronobinol include (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-
trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol, or (-)-delta-9-
(trans)-tetrahydrocannabinol.
(j) Narcotic drugs. Unless specifically excepted or
unless listed in another schedule, any material, compound,
mixture or preparation containing any of the following narcotic
drugs and their salts, as set forth below:
(i) Buprenorphine.